All patients presented severe aortic stenosis who were refused for conventional surgery. Procedure success, clinical outcomes and peri-procedural complications were prospectively assessed according to the Valve Academic Research Consortium (VARC)-2 criteria.
BACKGROUND Prospective randomized trials have demonstrated that transcatheter aortic valve replacement (TAVR) is an effective alternative to surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis at increased surgical risk, but reasons why left ventricular (LV) mass regresses more rapidly and to a greater extent after SAVR than TAVR despite a higher AV gradient after SAVR is unknown. We sought to determine why LV mass regression is greater after SAVR.
METHODS Baseline and serial echocardiography studies of patients randomized to SAVR with a bioprosthetic valve vs TAVR with a selfexpanding CoreValve were analyzed by an Echo Core Lab blinded to treatment and outcomes. Echocardiography measurements including AV gradient were performed according to established guidelines and LV mass was calculated using the formula of Devereaux et al:
dimension, PWT¼posterior wall thickness, and IVST¼interventricular septal thickness.
RESULTS Echo data were available in 389 TAVR and 353 SAVR patients (Table) . LVEDD, PWT, IVS, LV mass, and SV were similar in TAVR and SAVR at baseline. These variables were unchanged at discharge with TAVR. However, after SAVR at discharge, LV mass decreased from 227.45AE65.02 to 215.08AE59.02 gm (P¼0.002), and LVEDD from 5.01AE0.64 to 4.81AE0.65 cm (P<0.0001), although PWT and IVS were unchanged. 2D derived stroke volume (SV) also declined at discharge from 72.64AE27.04 mL to 58.93AE21.10 mL (P¼0.01) after SAVR, but not after TAVR (70.42AE27.21 mL to 70.36AE24.48 mL; P¼0.46). Similar changes were observed with Doppler derived SV. At 1 year, LV mass, SV and LVEDD remained smaller following SAVR vs. TAVR, a difference that persisted after exclusion of those with ! moderate aortic regurgitation (AR).
CONCLUSIONS Greater LV mass regression after SAVR is due to smaller post-operative LVEDD associated with lower SV after SAVR than TAVR. Further study is needed to identify the reasons for reduced SV after SAVR. BACKGROUND This is the first study comparing outcomes after transfemoral transcatheter aortic valve replacement (TAVR) with Symetis ACURATE (ACT) -a new device -, Medtronic CoreValve (MCV) and Edwards Sapien XT (SXT).
METHODS
We prospectively evaluated patients with severe aortic stenosis undergoing transfemoral TAVR at two centers coordinated by the same Heart Team. Study objectives were echocardiography findings and Valve Academic Research Consortium (VARC) at 30 days.
RESULTS
We evaluated 162 patients (ACT n¼48, MCV n¼57, SXT n¼57). Baseline clinical and imaging features are resumed in Table 1 . Immediately after the procedure, Device Success were lower with MCV (97.9% vs 86% vs 94.7%; p¼0,049), as well as Aortic Valve Area (1.90AE0.26 vs 1.81AE0.32 vs 2.01AE0.28; p¼0.002), with no differences in Mean Gradient (p¼0.752) or Moderate/Severe Aortic Regurgitation (p¼0.272). At 30 days, there were no significant difference in all-cause mortality (p¼0.298), cardiovascular mortality (p¼0.222), myocardial infarction (p¼0.776) and stroke (p¼0.999). Additionally, no differences were found in major vascular complications (p¼0.594), lifethreatening bleeding (0.378) and stage 3 acute kidney injury TAVR  SAVR  TAVR  SAVR  TAVR  SAVR  TAVR  SAVR  TAVR  SAVR 
